New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2014
09:06 EDTPTNPalatin Tech to benefit from FDA request, says Roth Capital
After the FDA requested more data about Sprout Pharmaceuticals' female sexual dysfunction drug, Roth Capital thinks the FDA's request solidifies the path forward for female sexual health drugs overall. The firm thinks the FDA's request will help Palatin's bremelanotide for the treatment of female sexual dysfunction ,and it keeps a "Buy rating on the stock.
News For PTN From The Last 14 Days
Check below for free stories on PTN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 9, 2014
07:32 EDTPTNPalatin Tech reports Q4 EPS (4c), consensus 3c
Reports Q4 revenue $0, consensus $2.91M.
September 3, 2014
05:47 EDTPTNPalatin Tech licenses bremelanotide to Richter
Palatin Technologies and Gedeon Richter announced that they have entered into a collaboration and license agreement to co-develop and commercialize bremelanotide for female sexual dysfunction, or FSD, indications in the European Union, other European countries and additional selected countries. Richter is a European-based specialty pharmaceutical company with a strong focus in female health and annual sales of more than $1.6B. Under the terms of the agreement, Palatin will receive total upfront payments of $9.9M. Palatin and Richter will each contribute to the European co-development activities for obtaining regulatory approval in Europe. Palatin anticipates that its part of the European co-development activities will be cash neutral through the European regulatory filing stage. All sales, marketing, and commercial activities and associated costs in the licensed territory will be the sole responsibility of Richter.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use